Logo Logo Logo Logo Logo Logo
  • About us
    • About us
    • Our team
    • Join us
    • Contact us
    • Corporate social responsibility
    • Code of conduct
    • Amryt compliance
    • Aegerion Consent Decree
  • Patients and carers
    • Patients and carers
    • Homozygous familial hypercholesterolaemia
    • Lipodystrophy
    • Epidermolysis bullosa
    • Acromegaly
    • Advocacy
  • Healthcare professionals
    • Healthcare professionals
    • Our science
    • Trials and registries
    • Expanded access programme
    • Medical information enquiries
    • Grants and donations
    • Research study requests
  • Product portfolio
    • Product portfolio
    • Juxtapid® / Lojuxta®▼
    • Myalept® / Myalepta®▼
    • Mycapssa®
    • Pipeline
  • Newsroom
  • Investors
    • The Company
    • News
    • Reports and presentations
    • Stock information
    • Events
    • Corporate governance
    • AIM Delisting
    • Contingent Value Rights (CVR) FAQ
    • Analysts
    • Contacts and advisors
  • Business development
  • About us
    • About us
    • Our team
    • Join us
    • Contact us
    • Corporate social responsibility
    • Code of conduct
    • Amryt compliance
    • Aegerion Consent Decree
  • Patients and carers
    • Patients and carers
    • Homozygous familial hypercholesterolaemia
    • Lipodystrophy
    • Epidermolysis bullosa
    • Acromegaly
    • Advocacy
  • Healthcare professionals
    • Healthcare professionals
    • Our science
    • Trials and registries
    • Expanded access programme
    • Medical information enquiries
    • Grants and donations
    • Research study requests
  • Product portfolio
    • Product portfolio
    • Juxtapid® / Lojuxta®▼
    • Myalept® / Myalepta®▼
    • Mycapssa®
    • Pipeline
  • Newsroom
  • Investors
    • The Company
    • News
    • Reports and presentations
    • Stock information
    • Events
    • Corporate governance
    • AIM Delisting
    • Contingent Value Rights (CVR) FAQ
    • Analysts
    • Contacts and advisors
  • Business development

Reports and presentations

Presentations

Annual Reports

Quarterly Reports

Sec Filings

REGISTER FOR ALERTS

Presentations

03 November 2022 Amryt Pharma Corporate Overview November 2022 PDF
03 November 2022 Amryt Pharma Q3 2022 Analyst Call & Webcast Presentation PDF

Annual Reports

01 Jun 2022 Amryt Pharma plc Annual Report 2021 PDF
02 Feb 2022 Amryt Pharma plc (Company only) Accounts for period ended 31 December 2020 PDF
02 Feb 2022 Amryt Pharma plc (Company only) Accounts for period ended 31 July 2020 PDF
29 Jun 2021 Amryt Pharma plc Annual Report 2020 PDF
30 Jun 2020 Amryt Pharma plc Annual Report 2019 PDF
12 Jun 2019 Amryt Pharma plc Annual Report 2018 PDF
04 May 2018 Amryt Pharma plc Annual Report 2017 PDF
06 Apr 2017 Amryt Pharma Annual Report 2016 PDF
10 Jun 2016 Amryt Pharma Annual Report 2015 PDF
04 Sep 2015 Annual Report as at 31.03.2015 PDF

Quarterly Reports

03 November 2022 Q3 2022 Results PDF
04 August 2022 Q2 2022 Results
04 May 2022 Q1 2022 Results
09 Mar 2022 Q4 2021 Results
03 Nov 2021 Q3 2021 Results
06 Aug 2021 Q2 2021 Results
05 May 2021 Q1 2021 Results
04 Mar 2021 Q4 2020 Results
05 Nov 2020 Q3 2020 Results
06 Aug 2020 Q2 2020 Results
11 May 2020 Q1 2020 Results

Sec Filings

Amryt Pharma

We transform the lives of people affected by rare, debilitating conditions by providing innovative medicines that bring hope to those in greatest need.

Privacy policy | Terms and Conditions | Modern Slavery Statement
Cookie policy | Fraud warning
Accessibility | Sitemap

Copyright © 2022 Amryt Pharma plc